Investors underwhelmed with Leap's early-stage DKN-01 data; shares down 23% [Seeking Alpha]
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: Seeking Alpha
Investors underwhelmed with Leap's early-stage DKN-01 data; shares down 23%Thinly traded micro cap Leap Therapeutics (LPTX-23.1%) slumps on almost triple normal volume, albeit on turnover of only 321K shares, in apparent response to itsannouncement of preliminary results from the dose-escalation phase of its study assessing DKN-01 with Merck's KEYTRUDA (pembrolizumab) in patients with advanced esophagogastric cancer.In four evaluable patients naive to PD-inhibitor treatment, one experienced a partial response with a 66% reduction in target tumor volume while two had stable disease.Enrollment is ongoing.DKN-01 is a humanized IgG4 monoclonal antibody that binds toDickkopf-1 (DKK1), a protein associated with a poor prognosis in a range of cancers. Specifically, it inhibits a pathway called canonical Wnt/Beta-catenin which plays a key role in embryonic development, cell proliferation and differentiation.See all stocks on the move »Now read:Gilead: Yescarta Faces Unforeseen Hurdles »
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Leap Therapeutics Announces $40 Million Private PlacementPR Newswire
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
LPTX
Earnings
- 3/18/24 - Beat
LPTX
Sec Filings
- 4/11/24 - Form 8-K
- 3/18/24 - Form S-3
- 3/18/24 - Form 8-K
- LPTX's page on the SEC website